'World-first' vaccine designed by artificial intelligence

Cambridge scientists say they have, for the first time, tested a vaccine designed by AI.

Scientists have successfully tested an AI-designed universal coronavirus vaccine in humans for the first time, finding it to be safe and well tolerated. The vaccine generated immune responses against multiple coronaviruses, including SARS-CoV-2, SARS, and related bat viruses with pandemic potential. By targeting features shared across an entire virus family, it aims to provide protection even as viruses evolve.

Cambridge researchers have developed an AI-designed vaccine that has successfully completed an initial human safety trial, raising hopes that future vaccines could protect against known viruses, new variants, and even pathogens that have yet to emerge. The technology aims to provide protection across entire families of viruses.

A team of British researchers, led by scientists at the universities of Cambridge and Southampton, has developed the first vaccine designed entirely by artificial intelligence to be tested in humans. The vaccine aims to protect against entire families of viruses, including coronaviruses with pandemic potential.

Artificial intelligence has been used to develop a 'fundamentally new' type of vaccine that could protect against large swathes of viruses and prevent pandemics, say researchers. The team at the University of Cambridge say it is the first time a vaccine's key component has been designed entirely by AI and then trialled in people.

Researchers at the University of Cambridge have developed an experimental vaccine using AI, marking the first human test of a vaccine component designed entirely by AI. The approach aims to provide broad protection against entire families of viruses, including coronaviruses with pandemic potential.

Researchers at the University of Cambridge have developed a groundbreaking AI-generated vaccine designed to protect against entire families of viruses, even if they mutate. The vaccine has undergone initial human trials targeting coronaviruses, showing modest immune response but substantial potential in fast-tracking vaccine development for pandemic-level threats.